Indivior Pharmaceuticals, Inc. (DELISTED) (INDV:DL)
36.28
+0.91
(+2.57%)
USD |
NASDAQ |
Nov 02, 16:00
Indivior Pharmaceuticals EPS Diluted (Quarterly) : 1.123 for Sept. 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 1.123 |
| June 30, 2026 | 0.9839 |
| March 31, 2026 | 0.6899 |
| December 31, 2025 | 0.816 |
| September 30, 2025 | 0.3256 |
| June 30, 2025 | 0.1429 |
| March 31, 2025 | 0.376 |
| December 31, 2024 | 0.168 |
| September 30, 2024 | 0.1654 |
| June 30, 2024 | -0.7185 |
| March 31, 2024 | 0.4453 |
| December 31, 2023 | 0.3804 |
| September 30, 2023 | -0.9804 |
| June 30, 2023 | 0.2732 |
| March 31, 2023 | 0.3121 |
| December 31, 2022 | -1.341 |
| September 30, 2022 | 0.28 |
| June 30, 2022 | 0.3437 |
| March 31, 2022 | 0.2751 |
| December 31, 2021 | 0.2492 |
| September 30, 2021 | 0.15 |
| June 30, 2021 | 0.40 |
| March 31, 2021 | 0.5119 |
| December 31, 2020 | -0.0886 |
| Date | Value |
|---|---|
| September 30, 2020 | 0.05 |
| June 30, 2020 | 0.10 |
| March 31, 2020 | -1.113 |
| December 31, 2019 | -0.3763 |
| September 30, 2019 | 0.30 |
| June 30, 2019 | 0.50 |
| March 31, 2019 | 0.4362 |
| December 31, 2018 | 0.1648 |
| September 30, 2018 | 0.611 |
| June 30, 2018 | 0.45 |
| March 31, 2018 | 0.60 |
| December 31, 2017 | -1.00 |
| September 30, 2017 | 0.35 |
| June 30, 2017 | 0.50 |
| March 31, 2017 | 0.55 |
| December 31, 2016 | 0.50 |
| September 30, 2016 | -1.05 |
| June 30, 2016 | 0.40 |
| March 31, 2016 | 0.35 |
| December 31, 2015 | 0.25 |
| September 30, 2015 | 0.35 |
| June 30, 2015 | 0.45 |
| March 31, 2015 | 0.55 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Supernus Pharmaceuticals, Inc. | 0.3516 |
| Bristol Myers Squibb Co. | 1.053 |
| Eli Lilly & Co. | 7.221 |
| Ligand Pharmaceuticals, Inc. | -1.427 |
| Amneal Pharmaceuticals, Inc. | -0.0646 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 137.00M |
| Revenue (Quarterly) | 356.00M |
| Total Expenses (Quarterly) | 219.00M |
| Enterprise Value | 4.477B |
| Gross Profit Margin (Quarterly) | 85.67% |
| Profit Margin (Quarterly) | 38.48% |
| Earnings Yield | 9.96% |
| Operating Earnings Yield | 13.65% |
| Normalized Earnings Yield | 11.29 |